Labopharm's trazodone meets Phase III endpoint

Labopharm (TSX:DDS; NASDAQ:DDSS) said once-daily trazodone met the primary endpoint of a significant improvement in baseline Hamilton rating scale for depression (HAMD-17) total score compared with placebo in the Phase III Study 04ACL3-001 (p=0.0183). The double-blind, U.S. and Canadian trial enrolled 412 patients with major unipolar depressive disorder. In the eight-week trial, patients in the trazodone group were titrated every 3-4 days to a dose of up to 375mg/day. ...